Skip to main content

ASH 2018 - Chronic Lymphocytic Leukemia

ASH 2018 - Chronic Lymphocytic Leukemia

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

ASH 2018 - Chronic Lymphocytic Leukemia

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2018 - Chronic Lymphocytic Leukemia

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL

ASH 2018 - Chronic Lymphocytic Leukemia

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

ASH 2018 - Chronic Lymphocytic Leukemia

CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry

ASH 2018 - Chronic Lymphocytic Leukemia

The Combination of Ibrutinib with Anti-CD19 CAR T-Cells Shows a High Response Rate in the Treatment of CLL

Page 2 of 2
Results 11 - 19 of 19